A Phase 2/3 interventional study of REC-2282 and Placebo in Neurofibromatosis Type 2, sponsored by Recursion Pharmaceuticals Inc.. Terminated at 15 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Recursion Pharmaceuticals Inc. · Phase 2/3, Interventional, and Treatment
This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in participants with progressive NF2 mutated meningiomas.
Cohort A (Phase 2) will provide early data on efficacy and safety of REC-2282 in participants with progressive NF2 mutated meningiomas, and provide guidance for the dose in the confirmatory part of the study (Cohort B, Phase 3). The purpose of Cohort B of the study is to assess the efficacy and safety of REC-2282 compared with placebo in participants with progressive NF2 mutated meningiomas.
In both cohorts, there will be a screening period of up to 8 weeks, a treatment period, a 4-week safety follow-up period after the end of treatment, and a 6-month post-study follow-up. The first 8 participants enrolled in Cohort A will complete a food effect run-in sub study. At the end of the study period, participants may be offered participation in an open-label extension (OLE) period.
In Cohort A, adult participants will be randomized to one of two dose levels of REC-2282.
In Cohort B, participants will be randomized to REC-2282 treatment (dose to be determined from Cohort A) arm or placebo arm in a ratio of 2:1.
47 studies on the registry are indexed under Neurofibromatosis 2; 10 are open to participants now.
This study's enrollment of 25 is above the median of 21 across 36 interventional studies indexed under Neurofibromatosis 2.
Browse Neurofibromatosis 2 studies →Recursion Pharmaceuticals Inc. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult participants will receive REC-2282.
Drug: REC-2282
Adult participants will receive REC-2282.
Drug: REC-2282
Adolescent participants will receive REC-2282.
Drug: REC-2282
Participants will receive REC-2282.
Drug: REC-2282
Participants will receive placebo.
Drug: Placebo
Participants will receive REC-2282 3 times per week orally for 3 weeks followed by 1 week off for a 4-week cycle.
Also known as: AR-42, OSU-HDAC42, NSC-D736012
Participants will receive placebo orally 3 times per week for 3 weeks followed by 1 week off for a 4-week cycle.
Cohort A: Number of Participants with Progression-free survival (PFS) at 6 Months
In Cohort A, PFS is defined as the number of participants who are alive and progression-free at 6 months with progression defined as having an increase of 20% or more in the target tumor identified.
Time frame: 6 months
Cohort B: Number of Participants with PFS up to 3 years
In Cohort B, PFS is defined as the time from the date of randomization until disease progression or death from any cause, whichever occurs first.
Time frame: Up to 3 years
Cohort A: Change from Baseline in Target Tumor Volume at 6 Months
Time frame: 6 months
Cohort A: Number of Participants with PFS at 12 and 24 Months
In Cohort A, PFS is defined as the number of participants who are alive and progression-free at 12 and 24 months with progression defined as having an increase of 20% or more in the target tumor identified.
Time frame: 12 and 24 Months
Cohorts A and B: Objective Response Rate (ORR)
Time frame: Up to 3 years
Cohorts A and B: Disease Control Rate (DCR)
Time frame: Up to 3 years
Cohorts A and B: Time to Response (TTR)
Time frame: Up to 3 years
Cohorts A and B: Duration of Response (DOR)
Time frame: Up to 3 years
Cohorts A and B: Time to Surgery/radiation for Target Tumors
Time frame: Up to 3 years
Cohorts A and B: Maximum Observed Plasma Concentration (Cmax) of REC-2282
Time frame: Up to 3 years
Cohorts A and B: Time to Maximum Plasma Concentration (Tmax) of REC-2282
Time frame: Up to 3 years
Cohorts A and B: Area under the curve from 0 to 24hr (AUC) of REC-2282
Time frame: Predose to 24 hours postdose
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: REC-2282
Recursion Pharmaceuticals Inc.